News | June 15, 2022
CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
AstraZeneca also played a critical role in the global response to COVID-19.
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Subscribe To Our Newsletter & Stay Updated
